ASBP
Aspire Biopharma Holdings, Inc.NASDAQHealthcare$1.02+10.78%ClosedMarket Cap: $3.5M
As of 2026-04-06
Valuation
P/E (TTM)
—
PEG
—
P/B
-0.26
P/S
630.62
EV/EBITDA
-0.22
DCF Value
$-0.61
FCF Yield
-125.9%
Div Yield
0.0%
Margins & Returns
Gross Margin
-1.9%
Operating Margin
-312016.9%
Net Margin
-394725.1%
ROE
284.6%
ROA
-1865.7%
ROIC
395.3%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q4 2025 | $4.3K | -23.5% | $-16.0M | $-4.7M | $-16.26 | — |
| FY 2025 | $6.2K | -1.9% | $-19.4M | $-24.5M | $-16.38 | — |
| Q3 2025 | $1.9K | 45.5% | $-1.1M | $-1.9M | $-0.01 | — |
| Q2 2025 | $0.00 | NaN% | $-799.9K | $-2.0M | $-0.01 | — |
| Q1 2025 | $0.00 | NaN% | $-1.4M | $-15.9M | $-0.11 | — |
| Q4 2024 | $0.00 | NaN% | $-640.5K | $-8.9M | $-0.28 | — |
| FY 2024 | $0.00 | NaN% | $-3.1M | $-12.5M | $-0.38 | — |
| Q3 2024 | $0.00 | NaN% | $-215.3K | $-537.0K | $-0.02 | — |
| Q2 2024 | $0.00 | NaN% | $-501.0K | $-602.0K | $-0.02 | — |
| Q1 2024 | $0.00 | NaN% | $-2.5M | $-2.5M | $-0.07 | — |
| Q4 2023 | $0.00 | NaN% | $-403.0K | $-151.0K | $-0.00 | — |
| FY 2023 | $0.00 | NaN% | $-1.3M | $4.5M | $0.06 | — |